We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Advanced UTI Testing Solution Reduces Health Care Costs, Utilization and Antibiotic Resistance

By LabMedica International staff writers
Posted on 21 Jun 2023
Print article
Image: Guidance UTI is the only UTI test that leverages Pooled Antibiotic Susceptibility Testing (Photo courtesy of Pathnostics)
Image: Guidance UTI is the only UTI test that leverages Pooled Antibiotic Susceptibility Testing (Photo courtesy of Pathnostics)

Urinary Tract Infections (UTIs) result in a significant number of doctor appointments and emergency room visits every year, causing a significant global healthcare burden. Although some people can easily detect and treat infections with medical help, others suffering from recurrent or complicated UTIs often struggle, undergoing numerous antibiotic treatments. In these cases, or those involving high-risk individuals, promptly identifying and treating the infection before it progresses is crucial. Now, an innovative testing solution addresses this health issue by aiding doctors in selecting the most effective treatment plan for each patient, expediting the right treatment, and reducing UTI-related hospital visits and admissions.

Pathnostics’ (Irvine, CA, USA) Guidance UTI is an advanced diagnostic testing solution designed for the rapid identification and accurate treatment of recurrent, complicated, and persistent UTIs, particularly in high-risk patients. The test can identify recognized uropathogens and antibiotic resistance genes and employs a unique Pooled Antibiotic Susceptibility Testing (P-AST) technology. This provides personalized data on antibiotic sensitivity and resistance and is particularly adept at addressing polymicrobial infections that can affect antibiotic resistance due to bacterial interactions.

Contrary to standard urine cultures that can take 3-5 days and often produce numerous false negatives, Guidance UTI can identify specific uropathogens, even in cases of multiple organism presence, in less than a day from samples received at the lab. Moreover, it can identify potential treatment options to quickly manage polymicrobial infections, providing advanced data in situations where traditional treatment methods pose challenges. Real-world evidence has demonstrated that the Guidance UTI test is associated with decreased adverse outcomes, healthcare resource usage, and costs for complicated UTIs when compared to standard urine culture.

"UTIs place a significant burden on individuals' health, as well as our health care system and resources. When they are not effectively treated, complications can lead to substantial medical issues and expenses," said David Pauluzzi, CEO and co-founder, Pathnostics. "These new findings, combined with ongoing studies, support our mission of increasing access to advanced UTI testing that supports more informed treatment leading to improved outcomes."

Related Links:
Pathnostics 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Protein ‘signatures’ obtained via a blood sample can be used to predict the onset of 67 diseases (Photo courtesy of Queen Mary University of London)

Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.